ContraFect_LOGO_Web.jpg
ContraFect to Present at the 2nd Annual Superdrugs and Superbugs USA Conference
November 10, 2017 07:00 ET | ContraFect Corporation
YONKERS, N.Y., Nov. 10, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect_LOGO_Web.jpg
ContraFect Announces Third Quarter 2017 Financial Results
November 09, 2017 07:00 ET | ContraFect Corporation
YONKERS, N.Y., Nov. 09, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect_LOGO_Web.jpg
ContraFect to Present New Data on CF-301 at ID Week 2017
September 29, 2017 07:00 ET | ContraFect Corporation
YONKERS, N.Y., Sept. 29, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect_LOGO_Web.jpg
ContraFect to Present at The MicroCap Conference
September 28, 2017 07:00 ET | ContraFect Corporation
YONKERS, N.Y., Sept. 28, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect_LOGO_Web.jpg
ContraFect to Present at 2017 Cantor Fitzgerald Global Healthcare Conference
September 13, 2017 07:00 ET | ContraFect Corporation
YONKERS, N.Y., Sept. 13, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Announces Second Quarter 2017 Financial Results
August 09, 2017 07:00 ET | ContraFect Corporation
YONKERS, NY--(Marketwired - August 09, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect to Present New Clinical and Microbiological Data on CF-301 at ASM Microbe 2017
June 01, 2017 07:00 ET | ContraFect Corporation
YONKERS, NY--(Marketwired - June 01, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Chairman Steven C. Gilman Returns from Temporary Medical Leave
May 30, 2017 07:00 ET | ContraFect Corporation
YONKERS, NY--(Marketwired - May 30, 2017) - ContraFect Corporation (NASDAQ: CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics...
ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia
May 25, 2017 07:00 ET | ContraFect Corporation
YONKERS, NY--(Marketwired - May 25, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Announces First Quarter 2017 Financial Results
May 08, 2017 07:00 ET | ContraFect Corporation
YONKERS, NY--(Marketwired - May 08, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...